Savara

77 articles with Savara

• Savara Announces Senior Management Changes

  9/11/2020

  Rob Neville Resigns as Chairman and Chief Executive Officer Matthew Pauls Appointed Chairman and Interim Chief Executive Officer AUSTIN, Texas--( BUSINESS WIRE )-- Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced that Rob Neville has resigned as the Company’s Chief Executive Officer (CEO) and from the Board of Directors, effective immediately, to pursue other opportunities. The Company’s Board of Directors has appo

• Savara to Present at the 22nd Annual H.C. Wainwright Annual Investment Conference Being Held Virtually

  9/9/2020

  Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced that Savara management will be presenting at the H.C. Wainwright Annual Investment Conference on Wednesday, September 16, 2020 at 3:00 PM EDT/12:00 PM PDT. Interested parties can access a live audio webcast on the Investors page of the Sav

• Savara Announces New England Journal of Medicine (NEJM) Publication of IMPALA Study Results

  9/8/2020

  Savara Announces New England Journal of Medicine ( NEJM ) Publication of IMPALA Study Results Inhaled Molgramostim Improved Outcomes that Reflect Physiological, Radiological, Biochemical, and Clinical Manifestations of aPAP AUSTIN, Texas--( BUSINESS WIRE )-- Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced that results from the Phase 3 IMPALA study were published online in NEJM. The manuscript, titled “Inhaled Molgramost

• Savara to Discontinue Exploratory ENCORE Study Evaluating Molgradex for the Treatment of NTM Lung Infection in People Living With Cystic Fibrosis (CF)

  9/3/2020

  Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced the decision to discontinue ENCORE, a 48-week, open-label, non-controlled Phase 2a exploratory clinical study of Molgradex for the treatment of nontuberculous mycobacterial (NTM) lung infection in people living with cystic fibrosis (CF). Molgradex, an inhaled formula

• Savara Reports Second Quarter 2020 Financial Results and Provides Business Update

  8/6/2020

  Announces Final Clinical Study Design for IMPALA 2, the Next Phase 3 Study of Molgradex in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

• Savara to Present at the 40th Annual Canaccord Genuity Global Growth Conference to be Held Virtually

  8/5/2020

  Savara to Present at the 40 th Annual Canaccord Genuity Global Growth Conference to be Held Virtually

• Savara to Report Second Quarter 2020 Financial Results and Provide Business Update

  7/30/2020

  Savara Inc. (NASDAQ: SVRA), an orphan lung disease company, today announced that the Company will report second quarter 2020 financial results and provide a business update on Thursday, August 6, 2020. Savara management will host a conference call/webcast at 4:30 p.m. Eastern Time (ET)/1:30 p.m. Pacific Time (PT). Shareholders and other interested parties may access the call by dialing (855) 239-3120 from the U.S.,

•  Savara to Present at the Jefferies Virtual Healthcare Conference

  5/27/2020

  Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced that Savara management will be presenting at the Jefferies Virtual Healthcare Conference on Wednesday, June 3, 2020 at 10:30 a.m. ET / 7:30 a.m. PT.

• Savara Announces Change of Date for 2020 Annual Meeting of Stockholders

  5/8/2020

  Meeting to Be Held on Friday, May 29, 2020 in Virtual-Only Format

• Savara Reports First Quarter 2020 Financial Results and Provides Business Update

  5/7/2020

  Company Announces Expected Design for IMPALA 2, the Next Phase 3 Study of Molgradex in aPAP

• Savara to Report First Quarter 2020 Financial Results and Provide Business Update

  4/30/2020

  Savara Inc., an orphan lung disease company, announced that the Company will report first quarter 2020 financial results and provide a business update on Thursday, May 7, 2020.

• Savara Obtains Global Rights to Develop and Commercialize Apulmiq

  4/2/2020

  Management to Host Conference Call / Webcast with Bronchiectasis Expert Dr. James Chalmers.

• Savara Provides Business Update in Response to COVID-19 Pandemic

  3/30/2020

  Savara Inc., an orphan lung disease company, provided an update on the impact COVID-19 has had on two of the Company’s clinical studies in cystic fibrosis.

• Savara Reports Fourth Quarter / Year-End 2019 Financial Results and Provides Business Update

  3/12/2020

  Announced Positive Results from IMPALA Open-Label Follow-Up Period That Demonstrate Continued Improvement After Longer Term Exposure to Molgradex

• Savara Granted Breakthrough Therapy Designation for Molgradex for the Treatment of Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

  12/30/2019

  Molgradexvis an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor, for the treatment of aPAP.

• Savara Announces the Appointment of Dr. An van Es-Johansson to Board of Directors

  12/3/2019

  Dr. van Es-Johansson, an expert in orphan drug development, is currently the Chief Medical Officer for AlzeCure Pharma, a Swedish pharmaceutical company with a primary focus on Alzheimer’s disease, where she is responsible for regulatory, clinical development, clinical operations, and pharmacovigilance

• Savara Announces New Employment Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

  11/27/2019

  Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced that on November 26, 2019, the independent members of the Company's Board of Directors granted Badrul Chowdhury, M.D., Ph.D., the Company's new Chief Medical Officer, an option to purchase 300,000 shares of the Company's common stock with an exercise price of $1.01 per share,

• Savara Appoints Badrul Chowdhury, M.D., Ph.D as Chief Medical Officer

  11/18/2019

  FDA Pulmonary, Allergy, and Rheumatology Division Veteran and Researcher Will Oversee the Company’s Medical and Regulatory Strategy

• Savara to Present at the Stifel 2019 Healthcare Conference

  11/12/2019

  Savara Inc., an orphan lung disease company, will be presenting at the Stifel 2019 Healthcare Conference on Tuesday, November 19, 2019 at 3:00 PM ET / 12:00 PM PT at the Lotte New York Palace Hotel.

• Savara Reports Third Quarter 2019 Financial Results and Provides Business Update

  11/7/2019

  Company in Discussions with Regulatory Agencies on Best Path Forward for the Molgradex Autoimmune Pulmonary Alveolar Proteinosis Program